Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03795363 · ClinicalTrials.gov registry record
Orkambi Treatment in 2 to 5 Year Old Children With CF
A clinical trial, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- 28
- Enrollment target
NCT03795363 is a clinical trial that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 28 participants.
The verdict
NCT03795363 has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
The purpose of this observational research study is to determine the effects of clinically prescribed Orkambi treatment on 2 to 5 year old children homozygous for the F508del Mutations in the Cystic fibrosis transmembrane conductance regulator (CFTR) gene on sleeping energy expenditure, growth status and gut health and function.
Interventions
- DRUG Orkambi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-04-10 |
| Est. Completion | 2021-06-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03795363
The ClinicalTrials.gov registry entry for NCT03795363 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Orkambi is the first listed.
NCT03795363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03795363 about?
NCT03795363 is a clinical study titled "Orkambi Treatment in 2 to 5 Year Old Children With CF". The purpose of this observational research study is to determine the effects of clinically prescribed Orkambi treatment on 2 to 5 year old children homozygous for the F508del Mutations in the Cystic fibrosis transmembrane conductance regulator (CFTR) gene on sleeping energy expenditure, growth statu...
What is the current status of trial NCT03795363?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2019-04-10. Estimated completion is 2021-06-16.
What interventions are being tested in trial NCT03795363?
The interventions under investigation include: Orkambi (DRUG).
Who is sponsoring clinical trial NCT03795363?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.